Eur Rev Med Pharmacol Sci 2020; 24 (14): 7816-7825
DOI: 10.26355/eurrev_202007_22286

From SARS-CoV to SARS-CoV2: a potential guide to better understanding of pathophysiology of the disease and potential therapeutic modality

P. Abbasi Pashaki, M. Habibi Roudkenar, F. Rahim, A. Ebrahimi

Department of Medical Biotechnology, School of Paramedicine, Guilan University of Medical Sciences, Rasht, Iran. Ebrahimi.am@outlook.com


Currently, the outbreak and spread of coronavirus disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), are increasing worldwide. Furthermore, it has been considered as a major challenge, which threatens human beings and affects all aspects of their life. Understanding the cellular and molecular pathophysiology of the disease is currently under the focus of investigations. Accordingly, this turns the human scientific community attention to find a solution for addressing the challenge. The development of vaccines and efficient therapeutic modality is critical. So, both primary and clinical scientists are not only trying to decipher the structure of SARS-CoV-2, but also attempting to understand the underlying molecular mechanisms that cause tissues and cell injuries. SARS-CoV and SARS-CoV2 are highly homologous and share a highly similar function and behavior patterns. Therefore, this might guide us toward decoding the molecular mechanisms that are behind the SARS-CoV2 pathologic effects. It is noteworthy to mention that, the undesired host immune reactions play important roles in the pathophysiology of the disease, and it also seems that, renin-angiotensin signaling (RAS) is a key contributor in this regard. In this review, we provided a vision, highlight as well as discussing on potential therapeutic targets that might be considered to address the COVID-19 challenge.

 

Free PDF Download

To cite this article

P. Abbasi Pashaki, M. Habibi Roudkenar, F. Rahim, A. Ebrahimi
From SARS-CoV to SARS-CoV2: a potential guide to better understanding of pathophysiology of the disease and potential therapeutic modality

Eur Rev Med Pharmacol Sci
Year: 2020
Vol. 24 - N. 14
Pages: 7816-7825
DOI: 10.26355/eurrev_202007_22286